



Integra LifeSciences Features the Advansys Mid and Hind Foot Plating Systems At Upcoming American Orthopaedic Foot and Ankle Society Meeting, July 13-15, 2007

PLAINSBORO, N.J., Jul 11, 2007 (PrimeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced that it will be featuring the Advansys(TM) Mid and Hind Foot Plating Systems at the 23rd Annual Summer Meeting of the American Orthopaedic Foot and Ankle Society Summer Meeting (AOFAS), Toronto, Ontario, Canada, July 13-15, 2007. The Advansys(TM) Mid and Hind Foot Plating Systems have an FDA clearance in the United States and a CE Mark Certification in the European Union. The Advansys(TM) systems were designed with the help of W. Hodges Davis, M.D., Bruce Cohen, M.D., Bob Anderson, M.D. and Carroll Jones, M.D., all practicing physicians with OrthoCarolina in Charlotte, North Carolina.

The Advansys(TM) Mid and Hind Foot Plating Systems consist of three separate plates designed specifically for mid and hind foot fusion and are manufactured from stainless steel alloy for strength and durability. All plates incorporate the patented Surfex (TM) locking technology, allowing the surgeon to securely position the plate for optimal deformity correction. Multiple screw sizes are available to accommodate the varying anatomy of the mid and hind foot.

Plating systems are frequently used to correct deformities of the foot, including fallen arches, arthritic changes, infections, and Charcot arthropathy (a condition occurring as a result of diabetic neuropathy or other diseases of the sensory nervous system). Based on available procedural data, Integra estimates that there are over 100,000 mid and hind foot reconstructive procedures performed annually, with an estimated market value of \$50 million.

Integra's Extremity Reconstruction sales organization will sell the Advansys(TM) Mid and Hind Foot Plating Systems. The Extremity Reconstruction sales force includes over 75 U.S. sales specialists who focus on lower extremity fixation, upper extremity fixation, wound repair, tendon protection, and peripheral nerve repair/protection.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at www.integra-ls.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Advansys(TM) Mid and Hind Foot Plating Systems. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the Risk Factors included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2006, and information contained in subsequent filings with the Securities and Exchange Commission, could affect actual results.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
John B. Henneman, III, Executive Vice President
(609) 936-2481
jhenneman@Integra-LS.com
Gianna Sabella, Public Relations Manager
(609) 936-2389
gsabella@Integra-LS.com

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX